Platelet-to-Lymphocyte Ratio and Use of NSAIDs During the Perioperative Period as Prognostic Indicators in Patients With NSCLC Undergoing Surgery.
暂无分享,去创建一个
R. Mehran | Lei Feng | D. Rice | J. Cata | G. Mena | V. Gottumukkala | Andrea Rodríguez | Brenda M Lee | Jun Yu | Lei Feng | D. Rice
[1] H. Uncu,et al. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer , 2016, Wiener klinische Wochenschrift.
[2] A. Jemal,et al. Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.
[3] Z. Wang,et al. Negative Impact of Preoperative Platelet-Lymphocyte Ratio on Outcome After Hepatic Resection for Intrahepatic Cholangiocarcinoma , 2015, Medicine.
[4] T. Nagayasu,et al. Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[5] R. Mehran,et al. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study , 2015, Cancer medicine.
[6] P. Iyengar,et al. Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[7] N. Roche,et al. Systemic Inflammation, Nutritional Status and Tumor Immune Microenvironment Determine Outcome of Resected Non-Small Cell Lung Cancer , 2014, PloS one.
[8] D. Gomez,et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. , 2014, International journal of radiation oncology, biology, physics.
[9] J. Machiels,et al. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. , 2014, British journal of anaesthesia.
[10] Tongshan Wang,et al. Prognostic Value of PLR in Various Cancers: A Meta-Analysis , 2014, PloS one.
[11] B. Seliger,et al. Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity , 2014, Clinical Cancer Research.
[12] U. Langsenlehner,et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients , 2014, British Journal of Cancer.
[13] M. Seckl,et al. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer , 2014, British Journal of Cancer.
[14] Shuai Zhang,et al. Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway. , 2014, Toxicology letters.
[15] Diane D. Liu,et al. Perioperative beta-blocker use and survival in lung cancer patients. , 2014, Journal of clinical anesthesia.
[16] B. Tsui,et al. Impact of anesthesia for cancer surgery: Continuing Professional Development , 2013, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.
[17] T. Burnouf,et al. The platelet-cancer loop. , 2013, European journal of internal medicine.
[18] A. Tasdemir,et al. ABO blood groups are not associated with treatment response and prognosis in patients with local advanced non- small cell lung cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[19] Jia-xin Yang,et al. Pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy. , 2013, Chinese medical journal.
[20] M. Brock,et al. Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer , 2013, Cancer investigation.
[21] V. Bhatt,et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients , 2013, Medical Oncology.
[22] S. Tangjitgamol,et al. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer , 2012, Journal of gynecologic oncology.
[23] M. Roh,et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[24] C. Sautès-Fridman,et al. The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.
[25] Viren Asher,et al. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer , 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[26] A. Lucci,et al. Role of COX-2 in tumorospheres derived from a breast cancer cell line. , 2011, The Journal of surgical research.
[27] A. Nurden. Platelets, inflammation and tissue regeneration , 2011, Thrombosis and Haemostasis.
[28] C. Holmes,et al. The platelet contribution to cancer progression , 2011, Journal of thrombosis and haemostasis : JTH.
[29] G. Snyder,et al. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. , 2010, British journal of anaesthesia.
[30] A. Richmond,et al. Chemokines and chemokine receptors: new insights into cancer-related inflammation. , 2010, Trends in molecular medicine.
[31] O. Arrieta,et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study , 2010, BMC Cancer.
[32] Baolin Wu,et al. Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity. , 2008, The Annals of thoracic surgery.
[33] I. Bartal,et al. Perioperative Use of β-blockers and COX-2 Inhibitors May Improve Immune Competence and Reduce the Risk of Tumor Metastasis , 2008, Annals of Surgical Oncology.
[34] Alberto Mantovani,et al. Inflammation and cancer: back to Virchow? , 2001, The Lancet.